Navigation Links
ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call
Date:7/24/2008

PLYMOUTH, Minn., July 24 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq: EVVV) today announced a revised date to report its 2008 second quarter and year-to-date financial results. ev3 will now report its 2008 second quarter and year-to-date financial results on Monday, July 28, 2008, after regular market trading hours.

The company will host a conference call and webcast at 7:30 a.m. Central Time (8:30 a.m. Eastern Time) on Tuesday, July 29, 2008. ev3 management will review its second quarter operating results and future outlook, followed by a question and answer session.

The conference call will be available to interested parties through a live audio webcast at http://ir.ev3.net, where it will be archived and accessible for approximately 90 days. The live dial-in number for the call is 888-679-8033 (U.S.) or 617-213-4846 (International). The participant passcode is 64950600.

If you do not have access to the Internet and want to listen to an audio replay of the conference call, dial 888-286-8010 (U.S.) or 617-801-6888 (International) and enter passcode 10431647. The audio replay will be available beginning at 9:30 a.m. Central Time on Tuesday, July 29, 2008 until Tuesday, August 5, 2008.

About ev3 Inc.

Since its founding in 2000, ev3 has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of lower extremity vascular and neurovascular diseases. ev3's products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. The company offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today -- peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, thrombectomy catheters and occlusion balloons. More information about the company and its products can be found at http://www.ev3.net.

ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S. and other countries.


'/>"/>
SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Connecticut Hospice, Inc. Announces the Arrival of Six Nurse Scholars From The Henrietta Szold-Hadassah-Hebrew University School of Nursing
2. ThermoGenesis Announces 10 New BioArchive(R) System Distributors
3. Tepha Announces Appointment of John Hartnett as Executive Vice President and Chief Operating Officer
4. BD Announces Results for Third Fiscal Quarter
5. Gerbig Engineering Announces Availability of Cleanroom Utility Panel
6. The Palomino Group Announces Launch of Meeting Support Services Business Unit
7. Misys Announces Preliminary Results for the Year Ended 31 May 2008
8. Cardiome Announces Preferred Share Financing
9. Mercy Health Plans Announces New Name for Their Medicare Advantage Plans: Mercy Medicare Advantage
10. American Heart Associations Announces Call for Entries for Howard L. Lewis Achievement Award
11. The Risk Management and Patient Safety Institute Announces 2008/2009 Annual Risk Management Conference, Dates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... ... effectively destroyed the construction site and threatened numerous homes and businesses nearby, causing ... article on NBCLosAngeles.com. Los Angeles Area consulting firm Fire Protection Group, Inc. ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Axiad ... organizations, today announced it has partnered with WALLIX to expand its solution ... 800-171 . , There are a number of ways to address the authentication requirements ...
(Date:7/24/2017)... ... 24, 2017 , ... Puregraft, the global leader in the ... United States Patent Number 9,695,398 (the '398 patent) and South Korean Patent Number ... '324 patents cover methods and systems for optimizing fat grafts for current and ...
(Date:7/24/2017)... ... 2017 , ... A new report released today by FusionHealth, ... health care at scale, indicates record-breaking adherence results for the company’s obstructive sleep ... pressure (PAP) therapy, the most widely utilized treatment for OSA, typically range between ...
(Date:7/24/2017)... ... July 24, 2017 , ... Committed to eliminating ... enrolled over 100,000 children in their treatment program. Clubfoot is a pervasive problem ... where treatment is limited or non-existent. Without intervention, these children are destined to ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... and EDMONTON, Alberta , ... scientists and the University of Alberta in ... data in Nature,s partner journal, Schizophrenia 1 , ... predict instances of schizophrenia with 74% accuracy. This ... severity of specific symptoms in schizophrenia patients with ...
(Date:7/21/2017)... Did you know that PhRMA member companies invested $65.5 billion in ... brand medicines, generics and the supply chain account for 14 percent ... of this (7 percent)? Or that the United States ... investments in high-growth biopharmaceutical startups? ... The biopharmaceutical industry accounts ...
(Date:7/17/2017)... Fla. , July 17, 2017  MedX Holdings, ... branded medical testing, strengthening and rehabilitation equipment, today announced ... Machine Program. MedX is considered the gold standard for ... leader in specialized medical strengthening equipment. ... a lease with the physician or practice who prescribe ...
Breaking Medicine Technology: